AP
The startup develops targeted radiotherapy (TRT) treatments tailored to the clinical stage of cancer, utilizing precise delivery methods to enhance treatment efficacy. By introducing these TRT products to the Chinese market, the company aims to improve patient outcomes and access to effective cancer therapies.
Updated 20 months ago
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ACVC
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops targeted radiotherapy (TRT) treatments tailored to the clinical stage of cancer, utilizing precise delivery methods to enhance treatment efficacy. By introducing these TRT products to the Chinese market, the company aims to improve patient outcomes and access to effective cancer therapies.